SS
SNDX icon

Steve Schonfeld’s Syndax Pharmaceuticals SNDX Stock Holding History

Steve Schonfeld’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.17M Sell
236,717
-23,909
-9% -$497K 0.02% 635
2026
Q1 		$6.09M Buy
260,626
+247,526
+1,890% +$5.38M 0.04% 432
2025
Q4 		$275K Sell
13,100
-119,023
-90% -$2.08M ﹤0.01% 1603
2025
Q3 		$2.03M Sell
132,123
-132,621
-50% -$1.74M 0.01% 1022
2025
Q2 		$2.48M Buy
264,744
+218,349
+471% +$2.4M 0.02% 865
2025
Q1 		$570K Buy
46,395
+25,738
+125% +$363K ﹤0.01% 1528
2024
Q4 		$273K Sell
20,657
-166,806
-89% -$2.85M ﹤0.01% 1648
2024
Q3 		$3.61M Sell
187,463
-73,413
-28% -$1.52M 0.02% 650
2024
Q2 		$5.36M Sell
260,876
-524,768
-67% -$11M 0.03% 525
2024
Q1 		$18.7M Buy
785,644
+314,169
+67% +$7.01M 0.12% 186
2023
Q4 		$10.2M Buy
471,475
+253,062
+116% +$3.89M 0.07% 350
2023
Q3 		$3.17M Sell
218,413
-20,154
-8% -$381K 0.02% 680
2023
Q2 		$4.99M Buy
238,567
+91,001
+62% +$1.89M 0.04% 489
2023
Q1 		$3.12M Buy
147,566
+138,466
+1,522% +$3.44M 0.03% 574
2022
Q4 		$232K Buy
+9,100
New +$212K ﹤0.01% 1919
2022
Q1 		– Sell
-12,300
Closed -$269K – 2900
2021
Q4 		$269K Sell
12,300
-63,300
-84% -$1.17M ﹤0.01% 1557
2021
Q3 		$1.45M Sell
75,600
-43,801
-37% -$730K 0.01% 825
2021
Q2 		$2.05M Sell
119,401
-5,101
-4% -$93.4K 0.02% 703
2021
Q1 		$2.78M Sell
124,502
-32,628
-21% -$737K 0.03% 587
2020
Q4 		$3.5M Buy
157,130
+136,314
+655% +$2.83M 0.05% 479
2020
Q3 		$307K Buy
+20,816
New +$317K 0.01% 1078

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Steve Schonfeld's SNDX Position: Q2 2026 in Review

Steve Schonfeld reduced its Syndax Pharmaceuticals (SNDX) stake by 9.2% in Q2 2026, selling an estimated $497K and leaving 236,717 shares worth $5.17M. The position accounts for 0.02% of the portfolio, ranked #635.

Steve Schonfeld first reported a position in SNDX in Q3 2020 and has held it in 21 quarters since. The position peaked at $18.7M in Q1 2024. 240 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Steve Schonfeld held 236,717 shares of Syndax Pharmaceuticals worth $5.17M as of Q2 2026.
  • Steve Schonfeld sold 23,909 Syndax Pharmaceuticals shares in Q2 2026, an estimated $497K.
  • Syndax Pharmaceuticals made up 0.02% of Steve Schonfeld's portfolio in Q2 2026, its #635 holding.
  • Steve Schonfeld first reported a position in Syndax Pharmaceuticals in Q3 2020 and has held it in 21 quarters since.
  • Steve Schonfeld's Syndax Pharmaceuticals position peaked at $18.7M in Q1 2024.
  • 240 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.